<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03089905</url>
  </required_header>
  <id_info>
    <org_study_id>TREX TRIAL</org_study_id>
    <nct_id>NCT03089905</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Long-term Outcomes After Two Different Anaesthetics</brief_title>
  <acronym>TREX</acronym>
  <official_title>Neurodevelopmental Outcome After Standard Dose Sevoflurane Versus Low-dose Sevoflurane/Dexmedetomidine/Remifentanil Anaesthesia in Young Children- The TREX Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Murdoch Childrens Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sydney Children's Hospitals Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas, Southwestern Medical Center at Dallas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Children's Hospital, Melbourne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queensland Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Perth Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Women's and Children's Hospital, Adelaide</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Giannina Gaslini, Genoa, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Flinders Medical Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Murdoch Childrens Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is considerable evidence that most general anaesthetics modulate brain development in&#xD;
      animal studies. The impact is greater with longer durations of exposure and in younger&#xD;
      animals. There is great controversy over whether or not these animal data are relevant to&#xD;
      human clinical scenarios.&#xD;
&#xD;
      The changes seen in preclinical studies are greatest with GABA agonists and NMDA antagonists&#xD;
      such as volatile anaesthetics (eg sevoflurane), propofol, midazolam, ketamine, and nitrous&#xD;
      oxide. There is less evidence for an effect with opioid (such as remifentanil) or with alpha&#xD;
      2 agonists (such as dexmedetomidine).&#xD;
&#xD;
      Some, but not all, human cohort studies show an association between exposure to anaesthesia&#xD;
      in infancy or early childhood and later changes in cognitive tests, school performance or&#xD;
      risk of developing neurodevelopmental disorders. The evidence is weak due to possible&#xD;
      confounding.&#xD;
&#xD;
      A recent well designed cohort study (the PANDA study) comparing young children that had&#xD;
      hernia repair to their siblings found no evidence for a difference in a range of detailed&#xD;
      neuropsychological tests. In that study most children were exposed to up to two hours of&#xD;
      anaesthesia. The only trial (the GAS trial) has compared children having hernia repair under&#xD;
      regional or general anesthesia and has found no evidence for a difference in neurodevelopment&#xD;
      when tested at two years of age. The GAS and PANDA studies confirm the animal data that short&#xD;
      exposure is unlikely to cause any neurodevelopmental impact.&#xD;
&#xD;
      The impact of longer exposures is still unknown. In humans the strongest evidence for an&#xD;
      association between surgery and poor neurodevelopmental outcome is in infants having major&#xD;
      surgery. However, this is also the group where confounding is most likely.&#xD;
&#xD;
      The aim of our study is to see if a new combination of anaesthetic drugs results in a better&#xD;
      long-term developmental outcome than the current standard of care for children having&#xD;
      anaesthesia expected to last 2 hours or longer.&#xD;
&#xD;
      Children will be randomised to receive either a low dose&#xD;
      sevoflurane/remifentanil/dexmedetomidine or standard dose sevoflurane anaesthetic.&#xD;
&#xD;
      They will receive a neurodevelopmental assessment at 3 years of age to assess global&#xD;
      cognitive function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2017</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomised to receive either low-dose sevoflurane/dexmedetomidine/remifentanil OR standard dose sevoflurane anaesthesia.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Randomisation 1:1 will be stratified by site and age at exposure (less than 12 months and greater than or equal to 12 months). Randomisation will be in blocks of variable size. The treating anaesthetist will not be blinded to treatment arm. The assessing neuropsychologist and parents will be blinded to treatment arm.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Full Scale IQ</measure>
    <time_frame>3 years of age</time_frame>
    <description>Global cognitive function as assessed by the full scale IQ score of the Wechsler Preschool and Primary School Intelligence Scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of intra-operative hypotension</measure>
    <time_frame>150 minutes- duration of surgery (baseline)</time_frame>
    <description>Blood pressure measurements will be recorded during surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of intra-operative bradycardia</measure>
    <time_frame>150 minutes- duration of surgery (baseline)</time_frame>
    <description>Heart rate will be recorded during surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative pain</measure>
    <time_frame>60 minutes- after surgery</time_frame>
    <description>Pain scores will be recorded after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery</measure>
    <time_frame>60 minutes- after surgery</time_frame>
    <description>Time of removal of airway, eye-opening and discharge from PACU will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Language outcomes</measure>
    <time_frame>3 years of age</time_frame>
    <description>Clinical Evaluation of Language Fundamentals- Preschool, Version 2 (CELF-P2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attention/Executive Function/impulse control</measure>
    <time_frame>3 years of age</time_frame>
    <description>A Developmental NEuroPSYchological Assessment- Second Edition (NEPSY-2): Statue Subtest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Memory</measure>
    <time_frame>3 years of age</time_frame>
    <description>A Developmental NEuroPSYchological Assessment- Second Edition (NEPSY-2): Narrative memory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adaptive behaviour</measure>
    <time_frame>3 years of age</time_frame>
    <description>Adaptive Behavior Assessment System - Third Edition (ABAS-III)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Behavior</measure>
    <time_frame>3 years of age</time_frame>
    <description>Child Behavior Checklist (CBCL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Executive Function</measure>
    <time_frame>3 years of age</time_frame>
    <description>Behavior Rating of Executive Function- Preschool (BRIEF-P)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Skills</measure>
    <time_frame>3 years of age</time_frame>
    <description>Social Skills Improvement System (SSIS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Anesthesia</condition>
  <condition>Neurotoxicity</condition>
  <condition>Child Development</condition>
  <arm_group>
    <arm_group_label>Sevoflurane/dexmedetomidine/remifentanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine: loading dose of 1mcg/kg over 10 minutes followed by an infusion of at 1 mcg/kg/hr.&#xD;
Remifentanil: loading dose 1 mcg/kg over 2 minutes followed by an infusion starting at 0.1 mcg/kg/min or greater.&#xD;
Sevoflurane: end tidal concentration of 0.6 -0.8% or less.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>End tidal concentration of 2.5-3.0% or greater.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Experimental arm: end tidal concentration of 0.6 -0.8% or less. Active comparator arm: end tidal concentration of 2.5-3.0% or greater.</description>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_label>Sevoflurane/dexmedetomidine/remifentanil</arm_group_label>
    <other_name>Sevorane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Experimental arm: loading dose: 1 mcg/kg, infusion starting at 0.1 mcg/kg/min or greater.</description>
    <arm_group_label>Sevoflurane/dexmedetomidine/remifentanil</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Experimental arm: loading dose:1mcg/kg, infusion: 1 mcg/kg/hr.</description>
    <arm_group_label>Sevoflurane/dexmedetomidine/remifentanil</arm_group_label>
    <other_name>Precedex</other_name>
    <other_name>Dexmedetomidine Ever Pharma</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Younger than 2 years (chronological age)&#xD;
&#xD;
          -  Scheduled for anaesthesia that is expected to last at least 2 hours (and/or total&#xD;
             operating room time is scheduled to be at least 2.5 hours)&#xD;
&#xD;
          -  Has a legally acceptable representative capable of understanding the informed consent&#xD;
             document and providing consent on the participant's behalf.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known neurologic, chromosomal or congenital anomaly which is likely to be associated&#xD;
             with poor neurobehavioural outcome&#xD;
&#xD;
          -  Existing diagnosis of behavioural or neurodevelopmental disability&#xD;
&#xD;
          -  Prematurity (defined as &lt; 36 weeks gestational age at birth)&#xD;
&#xD;
          -  Birth weight less than 2 kg.&#xD;
&#xD;
          -  Congenital cardiac disease requiring surgery&#xD;
&#xD;
          -  Intracranial neurosurgery and intracranial craniofacial surgery (isolated cleft lip is&#xD;
             not an exclusion)&#xD;
&#xD;
          -  Previous cumulative exposure to general anaesthesia exceeding 2 hours&#xD;
&#xD;
          -  Planned future cumulative exposure to anaesthesia exceeding 2 hours before the age of&#xD;
             3 years.&#xD;
&#xD;
          -  Any specific contra-indication to any aspect of the protocol&#xD;
&#xD;
          -  Previous adverse reaction to any anaesthetic&#xD;
&#xD;
          -  Circumstances likely to make long term follow-up impossible&#xD;
&#xD;
          -  Living in a household where the primary language spoken at home is not a language in&#xD;
             which we can administer the Wechsler Preschool and Primary School Intelligence Scale&#xD;
&#xD;
          -  Planned postoperative sedation with any agent except opioids (e.g. benzodiazepines,&#xD;
             dexmedetomidine, ketamine, barbiturates, propofol, clonidine, chloral hydrate, and&#xD;
             other non-opioid sedatives). For example if such sedation is planned for&#xD;
             post-operative ventilation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew J Davidson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Children's Hospital, Melbourne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew J Davidson, MD</last_name>
    <phone>+61393455233</phone>
    <email>andrew.davidson@rch.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suzette J Sheppard, Bsc (Hons)</last_name>
    <phone>+61393454901</phone>
    <email>suzette.sheppard@mcri.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Ellen McCann</last_name>
      <email>Mary.McCann@childrens.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Charles Berde</last_name>
      <email>Charles.Berde@childrens.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mary Ellen McCann</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Berde</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Ward</last_name>
      <email>WardC3@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Chris Ward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Szmuk, MD</last_name>
      <phone>214-456-8559</phone>
      <email>Peter.Szmuk@UTSouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dean B Andropoulos, MD</last_name>
      <phone>832-826-5831</phone>
      <email>dra@bcm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shona Chung</last_name>
      <email>Shona.Chung@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Shona Chung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin J Skowno</last_name>
      <email>justin.skowno@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Justin J Skowno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queensland Children's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Lee-Archer</last_name>
      <email>pleearcher@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Women's and Children's Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Taverner</last_name>
      <email>fiona.taverner@sa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Taverner</last_name>
      <email>fiona.taverner@sa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew J Davidson, MD</last_name>
      <phone>+61393455233</phone>
      <email>andrew.davidson@rch.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Suzette J Sheppard</last_name>
      <phone>+61393454901</phone>
      <email>suzette.sheppard@mcri.edu.au</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew J Davidson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Perth Children's Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Britta von ungern Sternberg</last_name>
      <email>britta.regli-vonungern@health.wa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Britta von ungern Sternberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedale Infantile C.Arrigo Azienda Ospedaliera</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi Montagnini</last_name>
      <email>luigi.montagnini@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliero-universitaria di Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Caramelli</last_name>
      <email>fabio.caramelli@aosp.bo.it</email>
    </contact>
    <investigator>
      <last_name>Fabio Carameli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Meyer</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Lenares</last_name>
      <email>elena.lenares@meyer.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Disma</last_name>
      <email>nicoladisma@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nicola Disma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico - Clinica Mangiagalli</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Colantonio</last_name>
      <email>laura.colantonio@policlinico.mi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vittore Buzzi Children's Hospital</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Izzo</last_name>
      <email>francesca.izzo@asst-fbf-sacco.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beate Kuppers</last_name>
      <email>b.kuppers@ao-pisa.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Beate Kuppers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Bambino Gesù</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabella Tucci</last_name>
      <email>isabella.tucci@opbg.net</email>
    </contact>
    <investigator>
      <last_name>Isabella Tucci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 8, 2017</study_first_submitted>
  <study_first_submitted_qc>March 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2017</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The de-identified data set collected for this analysis of the TREX trial will be available six months after publication of the primary outcome.&#xD;
The study protocol, analysis plan and consent forms will also be available. The data may be obtained from the Murdoch Children's Research Institute by emailing andrew.davidson@rch.org.au.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>6 months after publication of primary outcome</ipd_time_frame>
    <ipd_access_criteria>Prior to releasing any data the following are required: a data access agreement must be signed between relevant parties, the TREX Trial Steering Committee must see and approve the analysis plan describing how the data will be analysed, there must be an agreement around appropriate acknowledgement and any additional costs involved must be covered. Data will only be shared with a recognised research institution which has approved the proposed analysis plan.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

